Alexion Pharmaceuticals Public Company

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. The company's three innovative therapies treat patients with four severe and ultra-rare diseases, and it is committed to developing additional therapies that have the potential to transform patients' lives. Alexion is best known for developing Soliris (eculizumab), the world's first approved terminal complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). It also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders-Strensiq (asfotase alfa) for patients with hypophosphatasia (HPP) and Kanuma (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL-D).